Key Takeaways
- FY24 delivered ahead of plan: Revenue touched INR2,177 crores against a INR2,000 crores projection, driven by volume gains, new launches and wallet-share expansion, while gross margins improved 200 bps to 52.3% on softer raw material costs.
- Q4 was a reset quarter, not a stall: Sequential revenue dipped slightly on product-mix seasonality, while the Red Sea crisis added INR9 crores of freight cost and Teva-plant hiring pushed expenses up; management treats both as transitory.
- The U.S. is the declared growth engine: Management is "very bullish," targeting a doubling of U.S. revenue from $100 million to $200 million in 1–2 years, with the newly acquired Teva plant reaching EBITDA breakeven this quarter.
- INR3,000 crores by FY26 is reaffirmed: The target stands, with U.S. scale-up as the primary driver and a maintained expectation of 20%+ margins at that revenue level.
- What to watch next quarter: Whether the Teva plant hits its promised EBITDA breakeven, the pace of U.S. revenue ramp, and any concrete announcement on the European market entry or M&A.
U.S. Market: The Doubling Ambition
- Scale-up thesis: Management sees the current $100 million base as "the tip of the iceberg" for a market the size of the U.S.; the plan rests on increased capacity, a broader product portfolio and a larger front-end presence.
- Teva plant as the enabler: The acquired facility has installed first-phase capacity of 300 crore tablets and is now scaling utilization; a second phase targeting 500 crore tablets is expected to begin in H2 FY25, with a 5-billion-unit capacity milestone coming after September.
- Margin trajectory: U.S. EBITDA margin was already better last year, and management expects operating leverage to lift it further as revenues increase; the plant is expected to break even at the EBITDA level from Q1 FY25 itself.
- Portfolio mix: The U.S. business is roughly 80% OTC and 20% prescription; management expects nominal growth to 40-plus monographs by end of FY25, with substantial launches during the year though no single product is expected to dominate revenue.
- Risk acknowledgment: When asked to name a key risk to the doubling target, management offered none, citing order-book visibility; on geopolitical risk, the response was candidly agnostic.
Mark Saldanha: "It's still a very small number for a market like U.S. So it's not something that is novel or is unique in any way but it's still at tip of the iceberg."
FY24 Performance & Q4 Headwinds
- Full-year drivers: Revenue growth came from volume gains, new product launches, increased wallet share of existing customers and addition of new customers, with moderate pricing pressure on U.S. Rx products.
- Gross margin expansion: FY24 gross margin improved from 50.3% to 52.3%, attributed mainly to a reduction in raw material prices and a favorable product mix; raw material costs are now seen as having hit bottom and are expected to be stable going forward.
- Q4 sequential softness: Revenue was slightly lower than Q3 due to product-mix seasonality but still above the INR500 crores-per-quarter projected run rate.
- Three cost headwinds compressed Q4 EBITDA: Freight rates and transit times nearly doubled from the Red Sea crisis, costing approximately INR9 crores; Teva-plant expenses rose with over 200 new hires; and a strategic inventory build in the U.S. warehouse added INR7 crores to stock reserves to mitigate supply-chain risk.
- Australia's reverse seasonality: Q4 is a stronger quarter for Australia because it is winter there, benefiting the pain and cough-and-cold portfolio; this partially offsets softness elsewhere.
Margin Outlook & Profitability
- Gross margin guardrail: Management expects gross margins to remain sustainably in the 50% to 52% range.
- EBITDA improvement path: Margins are expected to improve as operating efficiencies and operating leverage kick in, particularly from the U.S. business; management declined to put a number on a specific EBITDA margin ceiling but said better numbers are possible.
- Net margin at scale: At the INR3,000 crores revenue level, a net margin rate of 15% or more should be maintainable, with a possibility of improvement, not decline.
- Investment phase at Teva: The strategic decision to hire ahead of revenue and increase plant expenses is a near-term margin drag; profitability parameters are expected to start improving from here.
- Dividend policy held steady: The board recommended a final dividend of INR0.6 per share; management will stick to its policy of distributing one-third of free cash flow, citing capex priorities.
Geographic & Portfolio Expansion
- U.K. market: Management is "very optimistic and bullish," noting the company is among the top 5 in the U.K.; the U.S. and U.K. carry similar gross contribution margins but differ in operating costs due to distinct product portfolios.
- European market entry: The company is working toward entering the European market, hopefully within this financial year; an M&A route is in advanced dialogue but remains unpredictable, with nothing concrete yet.
- New product engine: Launches are happening every quarter and are expected to fuel growth through the year; key approvals were received from the USFDA and UK MHRA in pain management, cough and cold, and other therapeutic segments.
- Drug shortage non-opportunity: Management explicitly dismissed the idea that spot drug shortages in the U.S. represent a material opportunity, stating those shortages are not within the company's portfolio to monetize.
Mark Saldanha: "M&A is such an unpredictable thing even when we come to the last step it may not happen. So right now, there's nothing concrete to discuss or put pen to paper right now."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Teva plant EBITDA breakeven | Breakeven at EBITDA level | Q1 FY25 |
| Teva plant capacity expansion | Increase to 500 crore tablets capacity | Begin in H2 FY25 |
| Volume growth | 15% volume growth | FY25 |
| Gross margin range | Sustain at 50% to 52% | Ongoing |
| U.S. revenue doubling | From $100 million to $200 million | 1–2 years |
| INR3,000 crores revenue | Achieve with 20%+ margin | FY26 |
| U.S. monograph count | Grow to 40+ monographs | By end of FY25 |
| R&D spend | Around 2% of revenue | FY25 |
| European market entry | Enter European market | This financial year (hopefully) |
| Net margin floor at scale | 15%+ net margin, maintainable or better | When INR3,000 crores revenue achieved |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Operating revenue | ₹560 cr, +15.2% YoY |
| U.S. and North America revenue | ₹245 cr, +26.6% YoY |
| U.K. and EU formulation revenue | ₹230.8 cr, +12.9% YoY |
| Australia and New Zealand revenue | ₹63.3 cr, stable YoY |
| Gross margin | 51.8% |
| EBITDA | ₹109.6 cr, +0.1% YoY and -17.6% QoQ |
| EBITDA margin | 19.6% |
| FY24 operating revenue | ₹2,177 cr, +17.6% YoY |
| FY24 EBITDA | ₹459 cr, +35% YoY |
| FY24 EBITDA margin | 21.1%, +274 bps YoY |
| FY24 PAT | ₹314.9 cr, +18.7% YoY |
| FY24 EPS | ₹6.92 |
| FY24 gross margin | 52.3%, +207 bps YoY |
| FY24 cash from operations | ₹230 cr |
| FY24 free cash flow | ₹21.6 cr |
| FY24 capex | ₹208 cr, including ₹125 cr in Teva facility |
| Cash balance | ₹674 cr as of March 31, 2024 |
| Red Sea crisis cost impact | ~₹9 cr in Q4 |
| U.S. revenue mix (OTC/Rx) | 80% OTC, ~20% Rx |
| U.S. EBITDA margin | 10%+ |
| Ibuprofen revenue contribution | ~15% of total revenue |
| U.S. monographs | 25-30 currently, expected 40+ by end of FY25 |
| Teva plant capacity commercialized | 300 crore units, next phase to 5-plus billion units |
| Dividend per share | ₹0.6, 60% of ₹1 face value |